#GLP-1SpecialSeries
By VETTAPHARMA reporter: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely prescribed for type 2 diabetes and obesity, primarily for their effects on appetite regulation and satiety. While their physiological benefits are well documented, less is known about how these medications influence real-world eating behavior. A new population-based study turns attention away from clinical endpoints and toward an everyday decision point: supermarket food purchases.
Patient Population
The study included 1,177 adults drawn from the Danish SMIL (Health, Food, Purchases and Lifestyle) cohort, which collects detailed supermarket receipt data. Participants had a median age of 53 years (interquartile range, 45–61 years), and 52.5% were women. Among them, 293 individuals initiated GLP-1RA therapy between 2019 and 2022 and were matched 1:3 with 884 non-initiators based on sex, age, and income.
Study Design
This was a cross-sectional observational study using linked data from supermarket receipts and the Danish Prescription Registry. Food purchases were analyzed for the 365 days before and after GLP-1RA initiation (or a matched reference date for comparisons). To ensure comparable purchasing behavior, the analysis was restricted to individuals who spent at least kr100 on edible items in both periods. Nutritional composition was assessed per 100 g of food, and processing level was classified using the NOVA system.
Primary Endpoints
The primary endpoints were changes in nutritional quality and food processing level, specifically:
- Mean energy density (kcal/100 g)
- Mean content of sugar, carbohydrates, saturated fat, and protein (g/100 g)
- Proportion of foods classified as unprocessed, processed, or ultra-processed
Key Findings
After initiating GLP-1RA therapy, participants showed consistent shifts toward foods with lower energy density and less processing:
- Energy density decreased from 209.4 to 207.3 kcal/100 g (mean change −2.1; 95% CI, −3.3 to −1.0)
- Sugar decreased from 15.7 to 15.1 g/100 g (mean change −0.6; 95% CI, −0.7 to −0.5)
- Carbohydrates decreased from 19.8 to 19.3 g/100 g (mean change −0.5; 95% CI, −0.7 to −0.4)
- Saturated fat decreased slightly from 7.3 to 7.2 g/100 g
- Protein increased from 6.6 to 6.9 g/100 g (mean change +0.3; 95% CI, 0.2–0.3)
In parallel, the proportion of ultra-processed foods purchased declined by 1.2 percentage points, while unprocessed foods increased by 0.9 percentage points. These patterns were largely reversed among matched non-initiators.
Why It Matters
Although individual-level changes were modest, the authors note that such shifts may have meaningful implications at the population level, particularly as GLP-1RA use continues to rise. By capturing real-world purchasing behavior rather than self-reported intake, the study provides insight into how pharmacologic appetite modulation may subtly reshape food environments beyond the clinic.
________________________________________
Source credit:
- Sørensen, K. K., Møller, F. T., Yazdanfard, P. D. W., Hasselbalch, R., Kragholm, K. H., Andersen, M. P., & Torp-Pedersen, C. (2026). Consumer food purchases after glucagon-like peptide-1 receptor agonist initiation. JAMA Network Open, 9(1), e2555449 Click here
Disclaimer:
The contents published on this platform are intended solely for informational and educational purposes. Reports, summaries, and discussions related to clinical trials are based on publicly available data, press releases, scientific publications, and regulatory disclosures available at the time of reporting. The information provided does not constitute medical advice, diagnosis, treatment recommendations, or endorsement of any drug, therapy, or clinical outcome. Clinical trial data are subject to change as studies progress, and results discussed may be preliminary, incomplete, or not yet peer-reviewed. Readers are strongly encouraged to refer to the original clinical trial records, regulatory filings, peer-reviewed articles or related sources for complete, accurate, and up-to-date information. Healthcare professionals and patients should consult qualified medical professionals and relevant regulatory authorities before making any healthcare or treatment decisions. Images used on this platform are illustrative in nature and are intended for conceptual and representational purposes only. They may not depict actual products, facilities, individuals, or events. The platform and its contributors disclaim any liability for actions taken based on the information presented.
